文献速递小儿麻醉心胸血管麻醉

抗纤溶药物预防小儿体外循环心脏手术出血:系统评价与Meta分析

Antifibrinolytic Drugs for the Prevention of Bleeding in Pediatric Cardiac Surgery on Cardiopulmonary Bypass: A Systematic Review and Meta-analysis.
PubMed 文献 · Anesth Analg · 2022-01-01

结果显示阿普洛欣、氨甲环酸和氨基己酸均减少24小时失血量与输血,但安全性数据不足,需大型对比试验确定最佳药物与剂量。

要点

  • 三种抗纤溶药物均减少小儿体外循环术后24小时失血量与输血。
  • 氨甲环酸异质性低,阿普洛欣中等,氨基己酸异质性高。
  • 现有研究效能不足,无法评估死亡率及血栓等安全性差异。

核心结论

  • 现有数据表明阿普洛欣、氨甲环酸和氨基己酸三种抗纤溶药物均有效,应选择安全性最好的药物。
  • 因缺乏足够数据,需大型对比试验评估小儿中的相对安全性和合适剂量方案。

研究设计与样本

  • 系统评价与Meta分析,纳入1980至2019年发表的随机对照试验。
  • 检索MEDLINE、EMBASE、PubMed和CENTRAL数据库。
  • 纳入年龄小于18岁且无基础血液疾病患者的研究。
  • 每干预组参与者11至100例(中位数25,四分位距20.5),平均年龄13天至5.8岁,平均体重3.1至26.3 kg。

主要发现

  • 所有药物均减少24小时血制品输注。

关键数值与推荐

  • 氨甲环酸和阿普洛欣未显示明确的剂量-反应效应。
  • 研究效能不足,无法检测死亡率、血栓、过敏反应及肾或神经功能障碍的显著差异。
  • 方法学质量低至中等。

临床怎么用

  • 可考虑使用抗纤溶药物减少小儿体外循环心脏手术出血。
  • 选择药物时应优先考虑安全性特征最有利者。

局限性

  • 纳入研究方法学质量低至中等。
  • 研究效能不足,无法评估死亡率及安全性结局。
  • 缺乏足够数据确定最佳药物和剂量方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bleeding is one of the commonest complications affecting children undergoing cardiac surgery on cardiopulmonary bypass. Antifibrinolytic drugs are part of a multifaceted approach aimed at reducing bleeding, though sufficiently sized pediatric studies are sparse, and dosing algorithms are heterogeneous. Our objective was to evaluate the efficacy and safety of antifibrinolytic agents as well as the effectiveness of different dosing regimens in pediatric cardiac surgery using cardiopulmonary bypass. METHODS: We performed a systematic review and meta-analysis evaluating randomized controlled trials published between 1980 and 2019, identified by searching the databases MEDLINE, EMBASE, PubMed, and CENTRAL. All studies investigating patients <18 years of age without underlying hematological disorders were included. The primary outcome was postoperative bleeding; secondary end points included blood product transfusion, mortality, and safety (thromboses, anaphylaxis, renal or neurological dysfunction, and seizures). Different dosing regimens were compared. Studies were dual appraised, outcomes were reported descriptively and, if appropriate, quantitatively using the Review Manager 5 (REVMAN 5) software (The Cochrane Collaboration). RESULTS: Thirty of 209 articles were included, evaluating the following drugs versus control: aprotinin n = 14, tranexamic acid (TXA) n = 12, and epsilon-aminocaproic acid (EACA) n = 4. The number of participants per intervention group ranged from 11 to 100 (median, 25; interquartile range [IQR], 20.5) with a wide age span (mean, 13 days to 5.8 years) and weight range (mean, 3.1-26.3 kg). Methodological quality was low to moderate.All agents reduced mean 24-hour blood loss compared to control: aprotinin by 6.0 mL/kg (95% confidence interval [CI], -9.1 to -3.0; P = .0001), TXA by 9.0 mL/kg (95% CI, -11.3 to -6.8; P < .00001), and EACA by 10.5 mL/kg (95% CI, -21.1 to 0.0; P = .05). Heterogeneity was low for TXA (I2 = 29%; P = .19), moderate for aprotinin (I2 = 41%; P = .11), and high for EACA (I2 = 95%; P < .00001). All agents also reduced 24-hour blood product transfusion. There was no clear dose-response effect for TXA nor aprotinin. Studies were underpowered to detect significant differences in mortality, thromboses, anaphylaxis, and renal or neurological dysfunction. CONCLUSIONS: The available data demonstrate efficacy for all 3 antifibrinolytic drugs. Therefore, the agent with the most favorable safety profile should be used. As sufficient data are lacking, large comparative trials are warranted to assess the relative safety and appropriate dosing regimens in pediatrics.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Siemens K, Sangaran DP, Hunt BJ, et al. Antifibrinolytic Drugs for the Prevention of Bleeding in Pediatric Cardiac Surgery on Cardiopulmonary Bypass: A Systematic Review and Meta-analysis. Anesth Analg. 2022. PMID: 34633994. doi:10.1213/ANE.0000000000005760

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。